BOSHI(002698) 东北证券·2025-04-26 13:45Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected stock price increase of over 15% within the next six months [7]. Core Insights - The company is entering a high growth phase, with a backlog of orders amounting to 6.322 billion yuan, of which 79.61% are from intelligent manufacturing equipment [2]. - The company has partnered with Harbin Institute of Technology to develop humanoid robots, focusing on key technologies such as bionic motion structure design and intelligent perception [3]. - The company has invested in several robotics firms, holding 13.46% of Harbin Sizerui Intelligent Medical Equipment Co., Ltd. and 5.56% of Suzhou Zhuzheng Robotics Co., Ltd. [4]. Financial Summary - In 2024, the company achieved a revenue of 2.863 billion yuan, an increase of 11.59% year-on-year, while the net profit attributable to shareholders was 524 million yuan, a decrease of 1.76% [1]. - Revenue projections for 2025, 2026, and 2027 are 3.816 billion yuan, 3.981 billion yuan, and 4.180 billion yuan, respectively, with net profits expected to be 756 million yuan, 796 million yuan, and 804 million yuan [4][5]. - The company's earnings per share (EPS) for 2024 is projected at 0.52 yuan, increasing to 0.74 yuan in 2025 and 0.78 yuan in 2026 [5][13].